Daprodustat Bioequivalence and Food Effect Study

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

June 9, 2018

Study Completion Date

June 9, 2018

Conditions
Anaemia
Interventions
DRUG

Daprodustat 2 mg tablet

Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.

DRUG

Daprodustat 4 mg tablet

Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.

Trial Locations (1)

813-0017

GSK Investigational Site, Fukuoka

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03493386 - Daprodustat Bioequivalence and Food Effect Study | Biotech Hunter | Biotech Hunter